ADMA Biologics, Inc. (ADMA) Stock

ADMA Biologics, Inc. (ADMA) is a Healthcare stock trading at $8.29 (as of 2026-06-18), with a market capitalization of $1.80B and a trailing P/E of 12.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

ADMA Biologics, Inc. develops, manufactures, and markets specialty plasma-derived biologics, including IVIG products for primary humoral immunodeficiency and a product for acute exposure to Hepatitis B surface antigen. It also maintains a pipeline of plasma-derived therapeutics and operates source plasma collection facilities, with sales through distributors, sales agents, and specialty pharmacies in the U.S. and internationally.

Valuation — source: SEC EDGAR (first-party)
Price	$8.29
Market Cap	$1.80B
P/E Ratio	12.1
EV / EBITDA	8.8
Price / Book	4.88
Price / Sales	3.73
DCF Value (model)	$2.05
DCF Upside vs Price	-75.3%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$510.17M
Net Margin	28.8%
Return on Equity	42.4%
Debt / Equity	0.50
Current Ratio	6.95
Revenue Growth (YoY)	19.6%
EPS Growth (YoY)	-27.1%
FCF Growth (YoY)	-74.8%

Financial Health — source: SEC EDGAR
Altman Z-Score	10.29 (safe)
Piotroski F-Score	5/9 (moderate)

Valuation vs Sector & Industry
Stock P/E	12.1
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-42.4%
vs Industry	-30.1%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($380.39M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Adam S. Grossman
Employees	685
Country	US
IPO Date	2013-10-17

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.